Author: Béla Hunyady
View More View Less
  • 1 Kaposi Mór Oktató Kórház Belgyógyászati Osztály Kaposvár Tallián Gyula u. 20–32. 7400
  • | 2 Pécsi Tudományegyetem, Klinikai Központ I. Belgyógyászati Klinika Pécs
Restricted access

Cross Mark

A hepatitis C-vírus- (HCV-) fertőzés előkelő helyen áll a krónikus májbetegségek, a májcirrhosis, a májelégtelenség, a májrák és a májtranszplantáció okai között. A jelenlegi kombinált pegilált interferon + ribavirin (P+R) kezeléssel a krónikus C-vírus hepatitises (CHC) betegek alig fele válik tartósan vírusmentessé. Ezért kiterjedt kutatás zajlik új, direkt ható antivirális szerek (DAA) kifejlesztésére. Ennek eredményeként 2011-ben két új, a proteázgátló csoportba tartozó készítmény (boceprevir és telaprevir) törzskönyvezése várható. Az eddigi klinikai vizsgálatok tapasztalatai alapján mindkét készítmény a P+R kombináció mellett, harmadik szerként bizonyult hatásosnak. Bevezetésükkel másfélszeresére nőhet a tartós vírusmentességet elérők aránya a nehezen gyógyítható G1 genotípussal fertőzöttek körében. Lerövidülhet továbbá a kezelés időtartama, és a korábbi kezelésre nem reagáló betegek közel fele meggyógyulhat. Problémának látszik a DAA-kal szemben gyorsan kialakuló rezisztencia, aminek elkerülése kulcsfontosságú a tartós vírusmentesség eléréséhez. A közleményben a boceprevirrel és a telaprevirrel végzett klinikai vizsgálatok eredményeit tekintem át. Orv. Hetil., 2011, 152, 887–897.

  • Gervain J., Horváth G., Hunyady B. és mtsai: Ajánlás: Protokoll a krónikus C-hepatitisek antivirális kezelésére. Orv. Hetil., 2008, 149, 2479–2483.

    Hunyady B. , 'Ajánlás: Protokoll a krónikus C-hepatitisek antivirális kezelésére ' (2008 ) 149 Orv. Hetil. : 2479 -2483.

    • Search Google Scholar
  • Pawlotsky, J. M., Chevaliez, S., McHutchison, J. G.: The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology, 2007, 132, 1979–1998.

    McHutchison J. G. , 'The hepatitis C virus life cycle as a target for new antiviral therapies ' (2007 ) 132 Gastroenterology : 1979 -1998.

    • Search Google Scholar
  • Berman, K., Kwo, P. Y.: Boceprevir, an NS3 protease inhibitor of HCV. Clin. Liver Dis., 2009, 13, 429–439.

    Kwo P. Y. , 'Boceprevir, an NS3 protease inhibitor of HCV ' (2009 ) 13 Clin. Liver Dis. : 429 -439.

    • Search Google Scholar
  • Kwo, P. Y., Lawitz, E. J., McCone, J. és mtsai: Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet, 2010, 376, 705–716.

    McCone J. , 'Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial ' (2010 ) 376 Lancet : 705 -716.

    • Search Google Scholar
  • Kwo, P. Y., Lawitz, E. J., McCone, J. és mtsai: Response-guided therapy (RGT) for boceprevir (BOC) combination treatment? – Results from HCV SPRINT-1. Hepatology, 2009, 50 (Suppl. 1), 1035A (Abstract 1582).

    McCone J. , 'Response-guided therapy (RGT) for boceprevir (BOC) combination treatment? – Results from HCV SPRINT-1 ' (2009 ) 50 Hepatology : 1035A -.

    • Search Google Scholar
  • Poordad, F., McCone, J., Bacon, B. R. és mtsai: Boceprevir (BOC) combined with peginterferon alfa-2b/ribavirin (P/R) for treatment-naive patients with hepatitis C virus (HCV) genotype (G) 1: SPRINT-2 final results. Hepatology, 2010, 52 (Suppl. 1), 107A (Abstract LB-4).

    Bacon B. R. , 'Boceprevir (BOC) combined with peginterferon alfa-2b/ribavirin (P/R) for treatment-naive patients with hepatitis C virus (HCV) genotype (G) 1: SPRINT-2 final results ' (2010 ) 52 Hepatology : 107A -.

    • Search Google Scholar
  • Bronowicki, J. P., McCone, J., Bacon, B. R. és mtsai: Response-guided therapy (RGT) with boceprevir (BOC) + peginterferon alfa-2b/ribavirin (P/R) for treatment-naive patients with hepatitis C virus (HCV) genotype (G) 1 was similar to a 48-Wk fixed-duration regimen with BOC + P/R in SPRINT-2. Hepatology, 2010, 52 (Suppl. 1), 224A (Abstract LB-15).

    Bacon B. R. , 'Response-guided therapy (RGT) with boceprevir (BOC) + peginterferon alfa-2b/ribavirin (P/R) for treatment-naive patients with hepatitis C virus (HCV) genotype (G) 1 was similar to a 48-Wk fixed-duration regimen with BOC + P/R in SPRINT-2 ' (2010 ) 52 Hepatology : 224A -.

    • Search Google Scholar
  • Bacon, B. R., Gordon, S. C., Lawitz, E. J. és mtsai: HCV RESPOND-2 final results: high sustained virologic response among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir plus PEGINTRON (peginterferon alfa-2b)/ribavirin. Hepatology, 2010, 52 (Suppl. 1), 430A (Abstract 216).

    Lawitz E. J. , 'HCV RESPOND-2 final results: high sustained virologic response among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir plus PEGINTRON (peginterferon alfa-2b)/ribavirin ' (2010 ) 52 Hepatology : 430A -.

    • Search Google Scholar
  • Vierling, J. M., Ralston, R., Lawitz, E. és mtsai: Long-term outcomes following combination treatment with boceprevir plus Peg-Intron/Ribavirin (P/R) in patients with chronic hepatitis C, genotype 1 (CHC-G1). J. Hepatol., 2010, 52 (Suppl. 1), S470 (Abstract 2016).

    Lawitz E. , 'Long-term outcomes following combination treatment with boceprevir plus Peg-Intron/Ribavirin (P/R) in patients with chronic hepatitis C, genotype 1 (CHC-G1) ' (2010 ) 52 J. Hepatol. : S470 -.

    • Search Google Scholar
  • McHutchison, J. G., Everson, G. T., Gordon, S. C. és mtsai: Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med., 2009, 360, 1827–1838.

    Gordon S. C. , 'Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection ' (2009 ) 360 N. Engl. J. Med. : 1827 -1838.

    • Search Google Scholar
  • Hezode, C., Forestier, N., Dusheiko, G. és mtsai: Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med., 2009, 360, 1839–1850.

    Dusheiko G. , 'Telaprevir and peginterferon with or without ribavirin for chronic HCV infection ' (2009 ) 360 N. Engl. J. Med. : 1839 -1850.

    • Search Google Scholar
  • Marcellin, P., Forns, X., Goeser, T. és mtsai: Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology, 2011, 140, 459–468.

    Goeser T. , 'Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C ' (2011 ) 140 Gastroenterology : 459 -468.

    • Search Google Scholar
  • Forns, X., Marcellin, P., Ferenci, P. és mtsai: On-treatment response-guided therapy with telaprevir q8h or q12h combined with peginterferon alfa-2a or peginterferon alfa-2b and ribavirin in treatment-naive genotype 1 hepatitis C (Study C208). J. Hepatol., 2010, 52 (Suppl. 1), S26 (Abstract 56).

    Ferenci P. , 'On-treatment response-guided therapy with telaprevir q8h or q12h combined with peginterferon alfa-2a or peginterferon alfa-2b and ribavirin in treatment-naive genotype 1 hepatitis C (Study C208) ' (2010 ) 52 J. Hepatol. : S26 -.

    • Search Google Scholar
  • Jacobson, I. M., McHutchison, J. G., Dusheiko, G. M. és mtsai: Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment naive patients: final results of phase 3 ADVANCE study. Hepatology, 2010, 52 (Suppl. 1), 427A (Abstract 211).

    Dusheiko G. M. , 'Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment naive patients: final results of phase 3 ADVANCE study ' (2010 ) 52 Hepatology : 427A -.

    • Search Google Scholar
  • Sherman, K. E., Flamm, S. L., Afdhal, N. H. és mtsai: Telaprevir in combination with peginterferon alfa2a and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved an extended rapid viral response: final results of phase 3 ILLUMINATE study. Hepatology, 2010, 52 (Suppl. 1), 106A (LB-2).

    Afdhal N. H. , 'Telaprevir in combination with peginterferon alfa2a and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved an extended rapid viral response: final results of phase 3 ILLUMINATE study ' (2010 ) 52 Hepatology : 106A -.

    • Search Google Scholar
  • McHutchison, J. G., Manns, M. P., Muir, A. J. és mtsai: Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med., 2010, 362, 1292–1303.

    Muir A. J. , 'Telaprevir for previously treated chronic HCV infection ' (2010 ) 362 N. Engl. J. Med. : 1292 -1303.

    • Search Google Scholar
  • Manns, M. P., Muir, A. J., Adda, N. és mtsai: Improved sustained virologic response (SVR) rates in „difficult-to-cure” patients treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: an analysis from the PROVE3 study. J. Hepatol., 2010, 52 (Suppl. 1), S115 (Abstract 274).

    Adda N. , 'Improved sustained virologic response (SVR) rates in „difficult-to-cure” patients treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: an analysis from the PROVE3 study ' (2010 ) 52 J. Hepatol. : S115 -.

    • Search Google Scholar
  • Berg, T., McHutchison, J. G., Adda, N. és mtsai: SVR with telaprevir, peginterferon alfa-2a and ribavirin in HCV patients with well-characterized prior null response, partialresponse, viral breakthrough or relapse after PR. J. Hepatol., 2010, 52 (Suppl. 1), S2 (Abstract 4).

    Adda N. , 'SVR with telaprevir, peginterferon alfa-2a and ribavirin in HCV patients with well-characterized prior null response, partialresponse, viral breakthrough or relapse after PR ' (2010 ) 52 J. Hepatol. : S2 -.

    • Search Google Scholar
  • Telaprevir combination therapy boosts sustained response rates for previously treated hepatitis C patients. Results of the REALIZE study. Press release, 9 Oct 2010. Forrás: http://www.hivandhepatitis.com/hep_c/news/2010/0910_2010_a.html

  • Bartenschlager, R., Lohmann, V.: Replication of hepatitis C virus. J. Gen. Virol., 2000, 81, 1631–1648.

    Lohmann V. , 'Replication of hepatitis C virus ' (2000 ) 81 J. Gen. Virol. : 1631 -1648.

  • Kuntzen, T., Timm, J., Berical, A. és mtsai: Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology, 2008, 48, 1769–1778.

    Berical A. , 'Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients ' (2008 ) 48 Hepatology : 1769 -1778.

    • Search Google Scholar
  • Ozeki, I.: Safety and a antiviral activity of a monotherapy with a MP-424 for 24 weeks in naive patients with chronic hepatitis C virus genotype 1b infection. J. Hepatol., 2009, 50 (Suppl. 1), S350 (Abstract 963).

    Ozeki I. , 'Safety and a antiviral activity of a monotherapy with a MP-424 for 24 weeks in naive patients with chronic hepatitis C virus genotype 1b infection ' (2009 ) 50 J. Hepatol. : S350 -.

    • Search Google Scholar
  • Sarrazin, C., Hong, J., Lim, S. és mtsai: Incidence of virologic escape observed during ITMN-191 (R7227) monotherapy is genotype dependent, associated with a specific NS3 substitution, and suppressed upon combination with peginterferon alfa-2a/ribavirin. J. Hepatol., 2009, 50 (Suppl. 1), S350 (Abstract 964).

    Lim S. , 'Incidence of virologic escape observed during ITMN-191 (R7227) monotherapy is genotype dependent, associated with a specific NS3 substitution, and suppressed upon combination with peginterferon alfa-2a/ribavirin ' (2009 ) 50 J. Hepatol. : S350 -.

    • Search Google Scholar
  • Chase, R., Skelton, A., Xia, E. és mtsai: A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors. Antiviral, Res., 2009, 84, 178–184.

    Xia E. , 'A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors ' (2009 ) 84 Antiviral, Res. : 178 -184.

    • Search Google Scholar
  • Romano, K. P., Ali, A., Royer, W. E. és mtsai: Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 20986–20991.

    Royer W. E. , 'Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding ' (2010 ) 107 Proc. Natl. Acad. Sci. U. S. A. : 20986 -20991.

    • Search Google Scholar
  • Gane, E. J., Roberts, S. K., Stedman, C. A. és mtsai: Combination therapy with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor in HCV: safety, pharmacokinetics, and virologic results from INFORM-1. J. Hepatol., 2009, 50 (S1), S380; AASLD 2009, Hepatology 2009, 50 (Suppl. 1), Abstract 193.

  • Zeuzem, S., Buggisch, P., Agarwal, K. és mtsai: Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PegIFN/RBV for up to 28 days in treatment naive, genotype 1 HCV subjects. Hepatology, 2010, 52 (Suppl. 1), 106A (LB-1).

    Agarwal K. , 'Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PegIFN/RBV for up to 28 days in treatment naive, genotype 1 HCV subjects ' (2010 ) 52 Hepatology : 106A -.

    • Search Google Scholar
  • Zeuzem, S., Asselah, T., Angus, P. és mtsai: Strong antiviral activity and safety of IFN-sparing treatment with the protease inhibitor BI 201335, the HCV polymerase inhibitor BI 207127 and ribavirin in patients with chronic hepatitis C. Hepatology, 2010, 52 (Suppl. 1), 223A (LB-7).

    Angus P. , 'Strong antiviral activity and safety of IFN-sparing treatment with the protease inhibitor BI 201335, the HCV polymerase inhibitor BI 207127 and ribavirin in patients with chronic hepatitis C ' (2010 ) 52 Hepatology : 223A -.

    • Search Google Scholar
  • Lok, A. S., Gardiner, D. F., Lawitz, E. és mtsai: Combination therapy with BMS-790052 and BMS-650032 alone or with PegIFN/RBV results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype 1 null responders. Hepatology, 2010, 52 (Suppl. 1), 223A (LB-8).

    Lawitz E. , 'Combination therapy with BMS-790052 and BMS-650032 alone or with PegIFN/RBV results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype 1 null responders ' (2010 ) 52 Hepatology : 223A -.

    • Search Google Scholar
  • Poordad, F., McCone, J. Jr., Bacon, B. R. és mtsai: Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med., 2011, 364, 1195–1206.

    Bacon B. R. , 'Boceprevir for untreated chronic HCV genotype 1 infection ' (2011 ) 364 N. Engl. J. Med. : 1195 -1206.

    • Search Google Scholar
  • Bacon, B. R., Gordon, S. C., Lawitz, E. és mtsai: Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med., 2011, 364, 1207–1217.

    Lawitz E. , 'Boceprevir for previously treated chronic HCV genotype 1 infection ' (2011 ) 364 N. Engl. J. Med. : 1207 -1217.

    • Search Google Scholar
  • Zeuzem, S., Andreone, P., Pol, S. és mtsai: REALIZE trial final results: Telaprevir-based regimen for genotype 1 hepatatitis C virus infection in patients with prior null-response, partial response or relapse to peginterferon/ribavirin. J. Hepatol., 2011, 54 (Suppl. 1), S3 (Abstract 5).

    Pol S. , 'REALIZE trial final results: Telaprevir-based regimen for genotype 1 hepatatitis C virus infection in patients with prior null-response, partial response or relapse to peginterferon/ribavirin ' (2011 ) 54 J. Hepatol. : S3 -.

    • Search Google Scholar
All Time Past Year Past 30 Days
Abstract Views 24 24 2
Full Text Views 15 11 0
PDF Downloads 2 2 0